Skip to main content

Anabolic–Androgenic Steroids

  • Chapter
  • First Online:
Drug Abuse and Addiction in Medical Illness

Abstract

The anabolic–androgenic steroids (AAS) are a family of hormones that includes the natural male hormone, testosterone, together with a group of synthetic derivatives of testosterone. These drugs are widely abused by men (and rarely, women) to gain muscle mass and lose body fat. Prior to about 1980, abuse of AAS was confined largely to elite competitive athletes, but in recent decades, AAS abuse has broken out of the athletic community and into the general population. Many modern AAS users have no specific athletic aspirations at all, but simply want to become bigger and more muscular. About 2–6% of men in many Western industrialized countries have used AAS, but AAS use is rare in Asian societies. Individuals with body image concerns, such as “muscle dysmorphia,” appear more prone to abuse AAS. Male muscularity is more strongly emphasized and rewarded in industrialized Western cultures than in Asia, and this difference likely explains the geographic distribution of AAS abuse. AAS cause few serious short-term medical effects, but over the long term may cause suppression of hypothalamic–pituitary–gonadal function, adverse effects on serum lipids, and cardiomyopathy. The most common psychiatric effects of AAS are mood disorders (typically hypomanic or manic syndromes during AAS exposure and depressive symptoms during AAS withdrawal); these are idiosyncratic, affecting a minority of AAS users, but are occasionally severe. A growing literature describes syndromes of AAS dependence, where individuals use AAS almost continuously despite adverse medical or psychiatric effects. Individuals displaying AAS abuse or dependence may also exhibit other forms of substance dependence. Unfortunately, AAS users rarely seek treatment, but this situation may change as the first large wave of illicit AAS users—those who first began AAS as youths in the 1980s—now reaches middle age and enters the age of risk for long-term cardiac, neuroendocrine, and psychiatric complications from these drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kanayama G, Hudson JI, Pope HG. Illicit anabolic-androgenic steroid use. Horm Behav. 2010;58(1):111–21.

    PubMed  CAS  Google Scholar 

  2. Pope HG, Brower KJ. Anabolic-androgenic steroid-related disorders. In: Sadock B, Sadock V, editors. Comprehensive textbook of psychiatry. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009. p. 1419–31.

    Google Scholar 

  3. David K, Dingemanse E, Freud J, Laquer E. Uber Krystallinisches mannliches Hormon Hoden (Testosteron), wirksamer als aus Harn oder aus Cholesterin Bereitetes Androsteron. Zeit Physiol Chem. 1935;233:281–2.

    CAS  Google Scholar 

  4. Wettstein A. Uber die kunstliche Herstellung des Testikelhormons Testosteron. Schweiz Med Wochenschr. 1935;16:912.

    Google Scholar 

  5. Kopera H. The history of anabolic steroids and a review of clinical experience with anabolic steroids. Acta Endocrinol. 1985;271:11–8.

    CAS  Google Scholar 

  6. Kouri EM, Pope Jr HG, Katz DL, Oliva P. Fat-free mass index in users and nonusers of anabolic-androgenic steroids. Clin J Sports Med. 1995;5(4):223–8.

    CAS  Google Scholar 

  7. Sheffield-Moore M, Urban RJ. An overview of the ­endocrinology of skeletal muscle. Trends Endocrinol Metab. 2004;15(3):110–5.

    PubMed  CAS  Google Scholar 

  8. Kanayama G, Boynes M, Hudson JI, Field AE, Pope HG, Jr. Anabolic steroid abuse among teenage girls: an illusory problem? Drug Alcohol Depend. 2007;88(2–3):156–62.

    Google Scholar 

  9. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther. 2001;23(9):1355–90.

    PubMed  CAS  Google Scholar 

  10. Basaria S, Wahlstrom JT, Dobs AS. Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab. 2001;86(11):5108–17.

    PubMed  CAS  Google Scholar 

  11. Wu FC. Endocrine aspects of anabolic steroids. Clin Chem. 1997;43(7):1289–92.

    PubMed  CAS  Google Scholar 

  12. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Treatment of anabolic-androgenic steroid dependence: emerging evidence and its implications. Drug Alcohol Depend. 2010;109(1–3):6–13.

    PubMed  CAS  Google Scholar 

  13. Frye CA. Some rewarding effects of androgens may be mediated by actions of its 5alpha-reduced metabolite 3alpha-androstanediol. Pharmacol Biochem Behav. 2007;86(2):354–67.

    PubMed  CAS  Google Scholar 

  14. Wood RI. Anabolic-androgenic steroid dependence? Insights from animals and humans. Front Neuroendocrinol. 2008;29(4):490–506.

    Google Scholar 

  15. Peters KD, Wood RI. Androgen dependence in hamsters: overdose, tolerance, and potential opioidergic mechanisms. Neuroscience. 2005;130(4):971–81.

    PubMed  CAS  Google Scholar 

  16. Kashkin KB, Kleber HD. Hooked on hormones? An anabolic ­steroid addiction hypothesis. JAMA. 1989;262(22):3166–70.

    PubMed  CAS  Google Scholar 

  17. Clark AS, Henderson LP. Behavioral and physiological responses to anabolic-androgenic steroids. Neurosci Biobehav Rev. 2003;27(5):413–36.

    PubMed  CAS  Google Scholar 

  18. Celerier E, Yazdi MT, Castane A, Ghozland S, Nyberg F, Maldonado R. Effects of nandrolone on acute morphine responses, tolerance and dependence in mice. Eur J Pharmacol. 2003;465(1–2):69–81.

    PubMed  CAS  Google Scholar 

  19. Johansson P, Ray A, Zhou Q, Huang W, Karlsson K, Nyberg F. Anabolic androgenic steroids increase beta-endorphin levels in the ventral tegmental area in the male rat brain. Neurosci Res. 1997;27(2):185–9.

    PubMed  CAS  Google Scholar 

  20. Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal syndromes. Endocr Rev. 2003;24(4):523–38.

    PubMed  CAS  Google Scholar 

  21. Kindlundh AM, Lindblom J, Bergstrom L, Nyberg F. The anabolic-androgenic steroid nandrolone induces alterations in the density of serotonergic 5HT1B and 5HT2 receptors in the male rat brain. Neuroscience. 2003;119(1):113–20.

    PubMed  CAS  Google Scholar 

  22. Kindlundh AM, Rahman S, Lindblom J, Nyberg F. Increased dopamine transporter density in the male rat brain following chronic nandrolone decanoate administration. Neurosci Lett. 2004;356(2):131–4.

    PubMed  CAS  Google Scholar 

  23. Schroeder JP, Packard MG. Role of dopamine receptor subtypes in the acquisition of a testosterone conditioned place preference in rats. Neurosci Lett. 2000;282(1–2):17–20.

    PubMed  CAS  Google Scholar 

  24. Daly RC, Su TP, Schmidt PJ, Pickar D, Murphy DL, Rubinow DR. Cerebrospinal fluid and behavioral changes after methyltestosterone administration: preliminary findings. Arch Gen Psychiatry. 2001;58(2):172–7.

    PubMed  CAS  Google Scholar 

  25. Lindqvist AS, Johansson-Steensland P, Nyberg F, Fahlke C. Anabolic androgenic steroid affects competitive behaviour, behavioural response to ethanol and brain serotonin levels. Behav Brain Res. 2002;133(1):21–9.

    PubMed  CAS  Google Scholar 

  26. Ricci LA, Rasakham K, Grimes JM, Melloni Jr RH. Serotonin-1A receptor activity and expression modulate adolescent anabolic/androgenic steroid-induced aggression in hamsters. Pharmacol Biochem Behav. 2006;85(1):1–11.

    PubMed  CAS  Google Scholar 

  27. Tamaki T, Shiraishi T, Takeda H, Matsumiya T, Roy RR, Edgerton VR. Nandrolone decanoate enhances hypothalamic biogenic amines in rats. Med Sci Sports Exerc. 2003;35(1):32–8.

    PubMed  CAS  Google Scholar 

  28. Sih R, Morley JE, Kaiser FE, Perry 3rd HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82(6):1661–7.

    PubMed  CAS  Google Scholar 

  29. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, et al. Testosterone replacement therapy improves mood in hypogonadal men–a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3578–83.

    PubMed  CAS  Google Scholar 

  30. Kanayama G, Amiaz R, Seidman S, Pope Jr HG. Testosterone supplementation for depressed men: current research and suggested treatment guidelines. Exp Clin Psychopharmacol. 2007;15(6):529–38.

    PubMed  CAS  Google Scholar 

  31. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3469–78.

    PubMed  CAS  Google Scholar 

  32. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88(6):2673–81.

    PubMed  CAS  Google Scholar 

  33. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839–53.

    PubMed  CAS  Google Scholar 

  34. Newshan G, Leon W. The use of anabolic agents in HIV disease. Int J STD AIDS. 2001;12(3):141–4.

    PubMed  CAS  Google Scholar 

  35. Johns K, Beddall MJ, Corrin RC. Anabolic steroids for the treatment of weight loss in HIV-infected individuals. Cochrane Database Syst Rev (Online). 2005;(4):CD005483.

    Google Scholar 

  36. Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab. 2000;85(1):60–5.

    PubMed  CAS  Google Scholar 

  37. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000;57(2):141–7; discussion 55–6.

    Google Scholar 

  38. Rabkin JG, Wagner GJ, McElhiney MC, Rabkin R, Lin SH. Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J Clin Psychopharmacol. 2004;24(4):379–85.

    PubMed  CAS  Google Scholar 

  39. Seidman SN, Spatz E, Rizzo C, Roose SP. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J Clin Psychiatry. 2001;62(6):406–12.

    PubMed  CAS  Google Scholar 

  40. Perry PJ, Yates WR, Williams RD, Andersen AE, MacIndoe JH, Lund BC, et al. Testosterone therapy in late-life major depression in males. J Clin Psychiatry. 2002;63(12):1096–101.

    PubMed  CAS  Google Scholar 

  41. Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord. 1998;48(2–3):157–61.

    PubMed  CAS  Google Scholar 

  42. Seidman SN, Miyazaki M, Roose SP. Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: randomized placebo-controlled clinical trial. J Clin Psychopharmacol. 2005;25(6):584–8.

    PubMed  CAS  Google Scholar 

  43. Pope Jr HG, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(1):105–11.

    PubMed  Google Scholar 

  44. Orengo CA, Fullerton L, Kunik ME. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol. 2005;18(1):20–4.

    PubMed  Google Scholar 

  45. Pope H, Amiaz R, Brennan B, Orr G, Weiser M, Kelly JF, et al. A parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. J Clin Psychopharmacol. 2010;30(2):126–34.

    PubMed  CAS  Google Scholar 

  46. Kanayama G, Hudson JI, Pope Jr HG. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend. 2008;98(1–2):1–12.

    PubMed  CAS  Google Scholar 

  47. Pope H, Phillips K, Olivardia R. The Adonis complex: the secret crisis of male body obsession. New York: Simon & Schuster; 2000.

    Google Scholar 

  48. Pope Jr HG, Olivardia R, Borowiecki 3rd JJ, Cohane GH. The growing commercial value of the male body: a longitudinal survey of advertising in women’s magazines. Psychother Psychosom. 2001;70(4):189–92.

    PubMed  Google Scholar 

  49. Pope Jr HG, Olivardia R, Gruber A, Borowiecki J. Evolving ideals of male body image as seen through action toys. Int J Eat Disord. 1999;26(1):65–72.

    PubMed  Google Scholar 

  50. Phillips W. Anabolic reference guide. Golden, CO: Mile High; 1985.

    Google Scholar 

  51. Phillips W. Anabolic reference update. Golden, CO: Mile High; 1991.

    Google Scholar 

  52. Duchaine D. The original underground steroid handbook. Santa Monica, CA: OEM; 1981.

    Google Scholar 

  53. Duchaine D. Underground steroid handbook II. Los Angeles, CA: HLR Technical Books; 1988.

    Google Scholar 

  54. One Hundred First United States Congress. The Steroid Trafficking Act of 1990. Washington: U.S. Government Printing Office; 1990.

    Google Scholar 

  55. Kanayama G, Pope Jr HG, Hudson JI. “Body image” drugs: a growing psychosomatic problem. Psychother Psychosom. 2001;70(2):61–5.

    PubMed  CAS  Google Scholar 

  56. Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc. 2006;38(4):644–51.

    PubMed  CAS  Google Scholar 

  57. Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med. 2004;32(2):534–42.

    PubMed  Google Scholar 

  58. Brennan BP, Kanayama G, Hudson JI, Pope HG. Illicit human growth hormone abuse in male weightlifters. Addict Behav. 2011;20(1):9–13.

    Google Scholar 

  59. Skarberg K, Nyberg F, Engstrom I. Multisubstance use as a feature of addiction to anabolic-androgenic steroids. Eur Addict Res. 2009;15(2):99–106.

    PubMed  Google Scholar 

  60. Kanayama G, Hudson JI, Pope Jr HG. Features of men with anabolic-androgenic steroid dependence: a comparison with nondependent AAS users and with AAS nonusers. Drug Alcohol Depend. 2009;102(1–3):130–7.

    PubMed  CAS  Google Scholar 

  61. Brower KJ. Anabolic steroid abuse and dependence in clinical practice. Phys Sportsmed. 2009;37:1–11.

    Google Scholar 

  62. Kanayama G, Cohane GH, Weiss RD, Pope HG. Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? J Clin Psychiatry. 2003;64(2):156–60.

    PubMed  Google Scholar 

  63. Kanayama G, Pope HG, Cohane G, Hudson JI. Risk factors for anabolic-androgenic steroid use among weightlifters: a case-control study. Drug Alcohol Depend. 2003;71(1):77–86.

    PubMed  Google Scholar 

  64. Pope Jr HG, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry. 1988;145(4):487–90.

    PubMed  Google Scholar 

  65. Pope Jr HG, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry. 1994;51(5):375–82.

    PubMed  CAS  Google Scholar 

  66. Reyes-Fuentes A, Veldhuis JD. Neuroendocrine physiology of the normal male gonadal axis. Endocrinol Metab Clin North Am. 1993;22(1):93–124.

    PubMed  CAS  Google Scholar 

  67. Swerdloff RS, Wang C, Hikim APS. Hypothalamic-pituitary-gonadal axis in men. In: Pfaff D, Arnold A, Etgen A, Fahrbach S, Rubin R, editors. Hormones, brain and behavior. San Diego: Elsevier; 2002. p. 1–36.

    Google Scholar 

  68. Fudala PJ, Weinrieb RM, Calarco JS, Kampman KM, Boardman C. An evaluation of anabolic-androgenic steroid abusers over a period of 1 year: seven case studies. Annu Clin Psychiatry. 2003;15(2):121–30.

    Google Scholar 

  69. Parrott AC, Choi PY, Davies M. Anabolic steroid use by amateur athletes: effects upon psychological mood states. J Sports Med Phys Fitness. 1994;34(3):292–8.

    PubMed  CAS  Google Scholar 

  70. Pope HG, Katz DL. Psychiatric effects of exogenous anabolic-androgenic steroids. In: Wolkowitz OM, Rothschild AJ, editors. Psychoneuroendocrinology: the scientific basis of clinical practice. Washington, DC: American Psychiatric Press; 2003. p. 331–58.

    Google Scholar 

  71. Kanayama G, Gruber AJ, Pope Jr HG, Borowiecki JJ, Hudson JI. Over-the-counter drug use in gymnasiums: an underrecognized substance abuse problem? Psychother Psychosom. 2001;70(3):137–40.

    PubMed  CAS  Google Scholar 

  72. Buckley WE, Yesalis 3rd CE, Friedl KE, Anderson WA, Streit AL, Wright JE. Estimated prevalence of anabolic steroid use among male high school seniors. JAMA. 1988;260(23):3441–5.

    PubMed  CAS  Google Scholar 

  73. McCabe SE, Brower KJ, West BT, Nelson TF, Wechsler H. Trends in non-medical use of anabolic steroids by U.S. college students: results from four national surveys. Drug Alcohol Depend. 2007;90(2–3):243–51.

    PubMed  Google Scholar 

  74. Handelsman DJ, Gupta L. Prevalence and risk factors for anabolic-androgenic steroid abuse in Australian high school students. Int J Androl. 1997;20(3):159–64.

    PubMed  CAS  Google Scholar 

  75. Melia P, Pipe A, Greenberg L. The use of anabolic-androgenic ­steroids by Canadian students. Clin J Sports Med. 1996;6(1):9–14.

    CAS  Google Scholar 

  76. Nilsson S, Baigi A, Marklund B, Fridlund B. The prevalence of the use of androgenic anabolic steroids by adolescents in a county of Sweden. Eur J Public Health. 2001;11(2):195–7.

    PubMed  CAS  Google Scholar 

  77. Thiblin I, Petersson A. Pharmacoepidemiology of anabolic androgenic steroids: a review. Fundam Clin Pharmacol. 2005;19(1):27–44.

    PubMed  CAS  Google Scholar 

  78. Pallesen S, Josendal O, Johnsen BH, Larsen S, Molde H. Anabolic steroid use in high school students. Subst Use Misuse. 2006;41(13):1705–17.

    PubMed  Google Scholar 

  79. Galduróz JC, Noto AR, Nappo SA, Carlini EA. Household survey on drug abuse in Brazil: study involving the 107 major cities of the country–2001. Addict Behav. 2005;30(3):545–56.

    PubMed  Google Scholar 

  80. Rachon D, Pokrywka L, Suchecka-Rachon K. Prevalence and risk factors of anabolic-androgenic steroids (AAS) abuse among adolescents and young adults in Poland. Sozial- und Praventivmedizin. 2006;51(6):392–8.

    PubMed  Google Scholar 

  81. Wanjek B, Rosendahl J, Strauss B, Gabriel HH. Doping, drugs and drug abuse among adolescents in the State of Thuringia (Germany): prevalence, knowledge and attitudes. Int J Sports Med. 2007;28(4):346–53.

    PubMed  CAS  Google Scholar 

  82. Yang CF, Gray P, Pope Jr HG. Male body image in Taiwan versus the West: Yanggang Zhiqi meets the Adonis complex. Am J Psychiatry. 2005;162(2):263–9.

    PubMed  Google Scholar 

  83. Gruber AJ, Pope Jr HG. Compulsive weight lifting and anabolic drug abuse among women rape victims. Compr Psychiatry. 1999;40(4):273–7.

    PubMed  CAS  Google Scholar 

  84. Gruber AJ, Pope Jr HG. Psychiatric and medical effects of anabolic-androgenic steroid use in women. Psychother Psychosom. 2000;69(1):19–26.

    PubMed  CAS  Google Scholar 

  85. Brower KJ. Anabolic steroid abuse and dependence. Curr Psychiatry Rep. 2002;4(5):377–87.

    PubMed  Google Scholar 

  86. Karasawa T, Shikata T, Smith RD. Peliosis hepatis. Report of nine cases. Acta Pathol Jpn. 1979;29(3):457–69.

    PubMed  CAS  Google Scholar 

  87. Schumacher J, Muller G, Klotz KF. Large hepatic hematoma and intraabdominal hemorrhage associated with abuse of anabolic steroids. New Engl J Med. 1999;340(14):1123–4.

    PubMed  CAS  Google Scholar 

  88. Bagia S, Hewitt PM, Morris DL. Anabolic steroid-induced hepatic adenomas with spontaneous haemorrhage in a bodybuilder. Aust NZ J Surg. 2000;70(9):686–7.

    CAS  Google Scholar 

  89. Socas L, Zumbado M, Perez-Luzardo O, Ramos A, Perez C, Hernandez JR, et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med. 2005;39(5):e27.

    PubMed  CAS  Google Scholar 

  90. Patil JJ, O’Donohoe B, Loyden CF, Shanahan D. Near-fatal spontaneous hepatic rupture associated with anabolic androgenic steroid use: a case report. Br J Sports Med. 2007;41(7):462–3.

    PubMed  CAS  Google Scholar 

  91. Dickerman RD, Pertusi RM, Zachariah NY, Dufour DR, McConathy WJ. Anabolic steroid-induced hepatotoxicity: is it overstated? Clin J Sports Med. 1999;9(1):34–9.

    CAS  Google Scholar 

  92. Herlitz LC, Markowitz GS, Farris AB, Schwimmer JA, Stokes MB, Kunis C, et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol. 2010;21(1):163–72.

    PubMed  CAS  Google Scholar 

  93. Nottin S, Nguyen LD, Terbah M, Obert P. Cardiovascular effects of androgenic anabolic steroids in male bodybuilders determined by tissue Doppler imaging. Am J Cardiol. 2006;97(6):912–5.

    PubMed  CAS  Google Scholar 

  94. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis. 1998;41(1):1–15.

    PubMed  CAS  Google Scholar 

  95. Di Bello V, Giorgi D, Bianchi M, Bertini A, Caputo MT, Valenti G, et al. Effects of anabolic-androgenic steroids on weight-lifters’ myocardium: an ultrasonic videodensitometric study. Med Sci Sports Exerc. 1999;31(4):514–21.

    PubMed  Google Scholar 

  96. D’Andrea A, Caso P, Salerno G, Scarafile R, De Corato G, Mita C, et al. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis (Commentary). Br J Sports Med. 2007;41(3):149–55.

    PubMed  Google Scholar 

  97. Kasikcioglu E, Oflaz H, Umman B, Bugra Z. Androgenic anabolic steroids also impair right ventricular function. Int J Cardiol. 2009;134(1):123–5.

    PubMed  Google Scholar 

  98. Ferenchick GS. Association of steroid abuse with cardiomyopathy in athletes. Am J Med. 1991;91(5):562.

    PubMed  CAS  Google Scholar 

  99. Stolt A, Karila T, Viitasalo M, Mantysaari M, Kujala UM, Karjalainen J. QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. Am J Cardiol. 1999;84(3):364–6. A9.

    PubMed  CAS  Google Scholar 

  100. Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med. 1999;17(5):851–7.

    PubMed  CAS  Google Scholar 

  101. Vogt AM, Geyer H, Jahn L, Schanzer W, Kubler W. Cardiomyopathy associated with uncontrolled self medication of anabolic steroids. Zeitschrift fur Kardiologie. 2002;91(4):357–62.

    PubMed  CAS  Google Scholar 

  102. Baggish AL, Weiner RB, Kanayama G, Hudson JI, Picard MH, Hutter AM, et al. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circ Heart Fail. 2010;3:472–6.

    PubMed  Google Scholar 

  103. Kuipers H, Wijnen JA, Hartgens F, Willems SM. Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body builders. Int J Sports Med. 1991;12(4):413–8.

    PubMed  CAS  Google Scholar 

  104. Kouri EM, Pope Jr HG, Oliva PS. Changes in lipoprotein-lipid levels in normal men following administration of increasing doses of testosterone cypionate. Clin J Sports Med. 1996;6(3):152–7.

    CAS  Google Scholar 

  105. Lajarin F, Zaragoza R, Tovar I, Martinez-Hernandez P. Evolution of serum lipids in two male bodybuilders using anabolic steroids. Clin Chem. 1996;42(6 Pt 1):970–2.

    PubMed  CAS  Google Scholar 

  106. Ferenchick GS. Anabolic/androgenic steroid abuse and thrombosis: is there a connection? Med Hypoth. 1991;35(1):27–31.

    CAS  Google Scholar 

  107. Ferenchick G, Schwartz D, Ball M, Schwartz K. Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters. Am J Med Sci. 1992;303(2):78–82.

    PubMed  CAS  Google Scholar 

  108. McCarthy K, Tang AT, Dalrymple-Hay MJ, Haw MP. Ventricular thrombosis and systemic embolism in bodybuilders: etiology and management. Annu Thoracic Surg. 2000;70(2):658–60.

    CAS  Google Scholar 

  109. McNutt RA, Ferenchick GS, Kirlin PC, Hamlin NJ. Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. Am J Cardiol. 1988;62(1):164.

    PubMed  CAS  Google Scholar 

  110. Ferenchick GS, Adelman S. Myocardial infarction associated with anabolic steroid use in a previously healthy 37-year-old weight lifter. Am Heart J. 1992;124(2):507–8.

    PubMed  CAS  Google Scholar 

  111. Kennedy C. Myocardial infarction in association with misuse of anabolic steroids. Ulster Med J. 1993;62(2):174–6.

    PubMed  CAS  Google Scholar 

  112. Kennedy MC, Corrigan AB, Pilbeam ST. Myocardial infarction and cerebral haemorrhage in a young body builder taking anabolic steroids. Aust NZ J Med. 1993;23(6):713.

    CAS  Google Scholar 

  113. Kennedy MC, Lawrence C. Anabolic steroid abuse and cardiac death. Med J Aust. 1993;158(5):346–8.

    PubMed  CAS  Google Scholar 

  114. Dickerman RD, Schaller F, Prather I, McConathy WJ. Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids. Cardiology. 1995;86(2):172–3.

    PubMed  CAS  Google Scholar 

  115. Fisher M, Appleby M, Rittoo D, Cotter L. Myocardial infarction with extensive intracoronary thrombus induced by anabolic steroids. Br J Clin Pract. 1996;50(4):222–3.

    PubMed  CAS  Google Scholar 

  116. Hausmann R, Hammer S, Betz P. Performance enhancing drugs (doping agents) and sudden death–a case report and review of the literature. Int J Legal Med. 1998;111(5):261–4.

    PubMed  CAS  Google Scholar 

  117. Godon P, Bonnefoy E, Guerard S, Munet M, Velon S, Brion R, et al. Myocardial infarction and anabolic steroid use. A case report. Arch Mal Coeur Vaiss. 2000;93(7):879–83.

    PubMed  CAS  Google Scholar 

  118. Tischer KH, Heyny-von Haussen R, Mall G, Doenecke P. [Coronary thrombosis and ectasia of coronary arteries after long-term use of anabolic steroids]. Zeitschrift fur Kardiologie. 2003;92(4):326–31.

    PubMed  CAS  Google Scholar 

  119. Halvorsen S, Thorsby PM, Haug E. Acute myocardial infarction in a young man who had been using androgenic anabolic steroids. Tidsskr Nor Laegeforen. 2004;124(2):170–2.

    PubMed  Google Scholar 

  120. Thiblin I, Lindquist O, Rajs J. Cause and manner of death among users of anabolic androgenic steroids. J Forensic Sci. 2000;45(1):16–23.

    PubMed  CAS  Google Scholar 

  121. Boyadjiev NP, Georgieva KN, Massaldjieva RI, Gueorguiev SI. Reversible hypogonadism and azoospermia as a result of anabolic-androgenic steroid use in a bodybuilder with personality disorder. A case report. J Sports Med Phys Fitness. 2000;40(3):271–4.

    PubMed  CAS  Google Scholar 

  122. Menon DK. Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil Steril. 2003;79 Suppl 3:1659–61.

    PubMed  Google Scholar 

  123. van Breda E, Keizer HA, Kuipers H, Wolffenbuttel BH. Androgenic anabolic steroid use and severe hypothalamic-pituitary dysfunction: a case study. Int J Sports Med. 2003;24(3):195–6.

    PubMed  Google Scholar 

  124. Allnutt S, Chaimowitz G. Anabolic steroid withdrawal depression: a case report. Can J Psychiatry. 1994;39(5):317–8.

    PubMed  CAS  Google Scholar 

  125. Brower KJ. Withdrawal from anabolic steroids. Curr Ther Endocrinol Metab. 1997;6:338–43.

    PubMed  CAS  Google Scholar 

  126. Brower KJ, Blow FC, Beresford TP, Fuelling C. Anabolic-androgenic steroid dependence. J Clin Psychiatry. 1989;50(1):31–3.

    PubMed  CAS  Google Scholar 

  127. Malone Jr DA, Dimeff RJ. The use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. J Clin Psychiatry. 1992;53(4):130–2.

    PubMed  Google Scholar 

  128. Malone Jr DA, Dimeff RJ, Lombardo JA, Sample RH. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. Clin J Sport Med. 1995;5(1):25–31.

    PubMed  Google Scholar 

  129. Thiblin I, Runeson B, Rajs J. Anabolic androgenic steroids and suicide. Annu Clin Psychiatry. 1999;11(4):223–31.

    CAS  Google Scholar 

  130. Brower KJ, Blow FC, Young JP, Hill EM. Symptoms and correlates of anabolic-androgenic steroid dependence. Br J Addict. 1991;86(6):759–68.

    PubMed  CAS  Google Scholar 

  131. Brower KJ, Catlin DH, Blow FC, Eliopulos GA, Beresford TP. Clinical assessment and urine testing for anabolic-androgenic steroid abuse and dependence. Am J Drug Alcohol Abuse. 1991;17(2):161–71.

    PubMed  CAS  Google Scholar 

  132. Cole JC, Smith R, Halford JC, Wagstaff GF. A preliminary investigation into the relationship between anabolic-androgenic steroid use and the symptoms of reverse anorexia in both current and ex-users. Psychopharmacology. 2003;166(4):424–9.

    PubMed  CAS  Google Scholar 

  133. Freinhar JP, Alvarez W. Androgen-induced hypomania. J Clin Psychiatry. 1985;46(8):354–5.

    PubMed  CAS  Google Scholar 

  134. Annitto WJ, Layman WA. Anabolic steroids and acute schizophrenic episode. J Clin Psychiatry. 1980;41(4):143–4.

    PubMed  CAS  Google Scholar 

  135. Pope Jr HG, Katz DL. Bodybuilder’s psychosis. Lancet. 1987;1(8537):863.

    PubMed  Google Scholar 

  136. Cooper CJ, Noakes TD. Psychiatric disturbances in users of anabolic steroids. S Afr Med J. 1994;84:509–12.

    PubMed  CAS  Google Scholar 

  137. Stanley A, Ward M. Anabolic steroids–the drugs that give and take away manhood. A case with an unusual physical sign. Med Sci Law. 1994;34(1):82–3.

    PubMed  CAS  Google Scholar 

  138. Papazisis G, Kouvelas D, Mastrogianni A, Karastergiou A. Anabolic androgenic steroid abuse and mood disorder: a case report. Int J Neuropsychopharmacol. 2007;10(2):291–3.

    PubMed  CAS  Google Scholar 

  139. Choi PY, Parrott AC, Cowan D. High-dose anabolic steroids in strength athletes: effects upon hostility and aggression. Hum Psychopharmacol. 1990;5:349–56.

    Google Scholar 

  140. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. Eur Psychiatry. 2006;21(8):551–62.

    PubMed  Google Scholar 

  141. Wilson-Fearon C, Parrott AC. Multiple drug use and dietary restraint in a Mr. Universe competitor: psychobiological effects. Percept Motor Skills. 1999;88(2):579–80.

    PubMed  CAS  Google Scholar 

  142. Cooper CJ, Noakes TD, Dunne T, Lambert MI, Rochford K. A high prevalence of abnormal personality traits in chronic users of anabolic-androgenic steroids. Br J Sports Med. 1996;30(3):246–50.

    PubMed  CAS  Google Scholar 

  143. Bahrke MS, Wright JE, Strauss RH, Catlin DH. Psychological moods and subjectively perceived behavioral and somatic changes accompanying anabolic-androgenic steroid use. Am J Sports Med. 1992;20(6):717–24.

    PubMed  CAS  Google Scholar 

  144. Choi PY, Pope Jr HG. Violence toward women and illicit androgenic-anabolic steroid use. Ann Clin Psychiatry. 1994;6(1):21–5.

    PubMed  CAS  Google Scholar 

  145. Lefavi R, Reeve T, Newland M. Relationship between anabolic steroid use and selected psychological parameters in male bodybuilders. J Sports Behav. 1990;13:157–66.

    Google Scholar 

  146. Midgley SJ, Heather N, Davies JB. Levels of aggression among a group of anabolic-androgenic steroid users. Med Sci Law. 2001;41(4):309–14.

    PubMed  CAS  Google Scholar 

  147. Moss H, Panzak G, Tarter R. Personality, mood, and psychiatric symptoms among anabolic steroid users. Am J Addict. 1992;1:315–24.

    Google Scholar 

  148. Perry PJ, Andersen KH, Yates WR. Illicit anabolic steroid use in athletes. A case series analysis. Am J Sports Med. 1990;18(4):422–8.

    PubMed  CAS  Google Scholar 

  149. Perry PJ, Kutscher EC, Lund BC, Yates WR, Holman TL, Demers L. Measures of aggression and mood changes in male weightlifters with and without androgenic anabolic steroid use. J Forensic Sci. 2003;48(3):646–51.

    PubMed  Google Scholar 

  150. Yates WR, Perry P, Murray S. Aggression and hostility in anabolic steroid users. Biol Psychiatry. 1992;31(12):1232–4.

    PubMed  CAS  Google Scholar 

  151. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS, Toli PN. Psychiatric and hostility factors related to use of anabolic steroids in monozygotic twins. Eur Psychiatry. 2006;21(8):563–9.

    PubMed  Google Scholar 

  152. Pope Jr HG, Katz DL. Homicide and near-homicide by anabolic steroid users. J Clin Psychiatry. 1990;51(1):28–31.

    PubMed  Google Scholar 

  153. Hall RC, Hall RC, Chapman MJ. Psychiatric complications of anabolic steroid abuse. Psychosomatics. 2005;46(4):285–90.

    PubMed  Google Scholar 

  154. Talih F, Fattal O, Malone D Jr. Anabolic steroid abuse: psychiatric and physical costs. Cleve Clin J Med 2007;74(5):341–4, 346, 349–52.

    Google Scholar 

  155. Trenton AJ, Currier GW. Behavioural manifestations of anabolic steroid use. CNS Drugs. 2005;19(7):571–95.

    PubMed  CAS  Google Scholar 

  156. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513–54.

    Google Scholar 

  157. Bahrke MS, Yesalis 3rd CE. Weight training. A potential confounding factor in examining the psychological and behavioural effects of anabolic-androgenic steroids. Sports Med. 1994;18(5):309–18.

    PubMed  CAS  Google Scholar 

  158. Bahrke MS, Yesalis 3rd CE, Wright JE. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update. Sports Med. 1996;22(6):367–90.

    PubMed  CAS  Google Scholar 

  159. Björkqvist K, Nygren T, Björklund A-C, Björkqvist S-E. Testosterone intake and aggressiveness: real effect or anticipation? Aggress Behav. 1994;20(1):17–26.

    Google Scholar 

  160. Riem K, Hursey K. Using anabolic-androgenic steroids to enhance physique and performance: effects on moods and behavior. Clin Psychol Rev. 1995;15:235–56.

    Google Scholar 

  161. Friedl KE, Dettori JR, Hannan Jr CJ, Patience TH, Plymate SR. Comparison of the effects of high dose testosterone and 19-­nortestosterone to a replacement dose of testosterone on strength and body composition in normal men. J Steroid Biochem Mol Biol. 1991;40(4–6):607–12.

    PubMed  CAS  Google Scholar 

  162. Friedl KE, Jones RE, Hannan Jr CJ, Plymate SR. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. J Clin Endocrinol Metab. 1989;68(5):971–5.

    PubMed  CAS  Google Scholar 

  163. Hannan Jr CJ, Friedl KE, Zold A, Kettler TM, Plymate SR. Psychological and serum homovanillic acid changes in men administered androgenic steroids. Psychoneuroendocrinology. 1991;16(4):335–43.

    PubMed  CAS  Google Scholar 

  164. Matsumoto AM. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J Clin Endocrinol Metab. 1990;70(1):282–7.

    PubMed  CAS  Google Scholar 

  165. Forbes GB, Porta CR, Herr BE, Griggs RC. Sequence of changes in body composition induced by testosterone and reversal of changes after drug is stopped. JAMA. 1992;267(3):397–9.

    PubMed  CAS  Google Scholar 

  166. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab. 1994;79(2):561–7.

    PubMed  CAS  Google Scholar 

  167. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. New Engl J Med. 1996;335(1):1–7.

    PubMed  CAS  Google Scholar 

  168. Pope HG Jr, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry 2000;57(2):133–40; discussion 55–6.

    Google Scholar 

  169. Su TP, Pagliaro M, Schmidt PJ, Pickar D, Wolkowitz O, Rubinow DR. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA. 1993;269(21):2760–4.

    PubMed  CAS  Google Scholar 

  170. Tricker R, Casaburi R, Storer TW, Clevenger B, Berman N, Shirazi A, et al. The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men–a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3754–8.

    PubMed  CAS  Google Scholar 

  171. Yates WR, Perry PJ, MacIndoe J, Holman T, Ellingrod V. Psychosexual effects of three doses of testosterone cycling in normal men. Biol Psychiatry. 1999;45(3):254–60.

    PubMed  CAS  Google Scholar 

  172. Agren G, Thiblin I, Tirassa P, Lundeberg T, Stenfors C. Behavioural anxiolytic effects of low-dose anabolic androgenic steroid treatment in rats. Physiol Behav. 1999;66(3):503–9.

    PubMed  CAS  Google Scholar 

  173. Schmidt PJ, Berlin KL, Danaceau MA, Neeren A, Haq NA, Roca CA, et al. The effects of pharmacologically induced hypogonadism on mood in healthy men. Arch Gen Psychiatry. 2004;61(10):997–1004.

    PubMed  Google Scholar 

  174. Melloni Jr RH, Connor DF, Hang PT, Harrison RJ, Ferris CF. Anabolic-androgenic steroid exposure during adolescence and aggressive behavior in golden hamsters. Physiol Behav. 1997;61(3):359–64.

    PubMed  CAS  Google Scholar 

  175. DeLeon KR, Grimes JM, Melloni Jr RH. Repeated anabolic-androgenic steroid treatment during adolescence increases vasopressin V(1A) receptor binding in Syrian hamsters: correlation with offensive aggression. Horm Behav. 2002;42(2):182–91.

    PubMed  CAS  Google Scholar 

  176. Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychiatry. 1996;153(8):974–84.

    PubMed  CAS  Google Scholar 

  177. Fischer SG, Ricci LA, Melloni Jr RH. Repeated anabolic/androgenic steroid exposure during adolescence alters phosphate-activated glutaminase and glutamate receptor 1 (GluR1) subunit immunoreactivity in Hamster brain: correlation with offensive aggression. Behav Brain Res. 2007;180(1):77–85.

    PubMed  CAS  Google Scholar 

  178. Grimes JM, Melloni Jr RH. Prolonged alterations in the serotonin neural system following the cessation of adolescent anabolic-androgenic steroid exposure in hamsters (Mesocricetus auratus). Behav Neurosci. 2006;120(6):1242–51.

    PubMed  CAS  Google Scholar 

  179. Daly RC. Anabolic steroids, brain and behaviour. Irish Med J. 2001;94(4):102.

    CAS  Google Scholar 

  180. Daly RC, Su TP, Schmidt PJ, Pagliaro M, Pickar D, Rubinow DR. Neuroendocrine and behavioral effects of high-dose anabolic ­steroid administration in male normal volunteers. Psychoneu­roendocrinology. 2003;28(3):317–31.

    PubMed  CAS  Google Scholar 

  181. Conacher GN, Workman DG. Violent crime possibly associated with anabolic steroid use. Am J Psychiatry. 1989;146(5):679.

    PubMed  CAS  Google Scholar 

  182. Dalby JT. Brief anabolic steroid use and sustained behavioral reaction. Am J Psychiatry. 1992;149(2):271–2.

    PubMed  CAS  Google Scholar 

  183. Schulte HM, Hall MJ, Boyer M. Domestic violence associated with anabolic steroid abuse. Am J Psychiatry. 1993;150(2):348.

    PubMed  CAS  Google Scholar 

  184. Pope Jr HG, Kouri EM, Powell KF, Campbell C, Katz DL. Anabolic-androgenic steroid use among 133 prisoners. Compr Psychiatry. 1996;37(5):322–7.

    PubMed  Google Scholar 

  185. Thiblin I, Kristiansson M, Rajs J. Anabolic androgenic steroids and behavioural patterns among violent offenders. J Forensic Psychiatry Psychol. 1997;8:299–310.

    Google Scholar 

  186. Thiblin I, Parlklo T. Anabolic androgenic steroids and violence. Acta Psychiatr Scand Suppl. 2002;412:125–8.

    PubMed  Google Scholar 

  187. Klotz F, Garle M, Granath F, Thiblin I. Criminality among individuals testing positive for the presence of anabolic androgenic steroids. Arch Gen Psychiatry. 2006;63(11):1274–9.

    PubMed  Google Scholar 

  188. Klotz F, Petersson A, Isacson D, Thiblin I. Violent crime and substance abuse: a medico-legal comparison between deceased users of anabolic androgenic steroids and abusers of illicit drugs. Forensic Sci Int. 2007;173(1):57–63.

    PubMed  Google Scholar 

  189. Petersson A, Garle M, Holmgren P, Druid H, Krantz P, Thiblin I. Toxicological findings and manner of death in autopsied users of anabolic androgenic steroids. Drug Alcohol Depend. 2006;81(3):241–9.

    PubMed  CAS  Google Scholar 

  190. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104:1966–78.

    PubMed  Google Scholar 

  191. Alexander GM, Packard MG, Hines M. Testosterone has rewarding affective properties in male rats: implications for the biological basis of sexual motivation. Behav Neurosci. 1994;108(2):424–8.

    PubMed  CAS  Google Scholar 

  192. Arnedo MT, Salvador A, Martinez-Sanchis S, Gonzalez-Bono E. Rewarding properties of testosterone in intact male mice: a pilot study. Pharmacol Biochem Behav. 2000;65(2):327–32.

    PubMed  CAS  Google Scholar 

  193. Wood RI. Anabolic steroids: a fatal attraction? J Neuroendocrinol. 2006;18(3):227–8.

    PubMed  CAS  Google Scholar 

  194. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (revised edition). 3rd ed. Washington, DC: American Psychiatric Association; 1987.

    Google Scholar 

  195. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association; 1994.

    Google Scholar 

  196. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (Text Revision) (DSM-IV-TR). 4th ed. Washington: American Psychiatric Association; 2000.

    Google Scholar 

  197. Copeland J, Peters R, Dillon P. Anabolic-androgenic steroid use disorders among a sample of Australian competitive and recreational users. Drug Alcohol Depend. 2000;60(1):91–6.

    PubMed  CAS  Google Scholar 

  198. Midgley SJ, Heather N, Davies JB. Dependence-producing potential of anabolic-androgenic steroids. Addict Res. 1999;7:539–50.

    Google Scholar 

  199. Gridley DW, Hanrahan SJ. Anabolic-androgenic steroid use among male gymnasium participants: knowledge and motives. Sports Health. 1994;12:11–4.

    Google Scholar 

  200. Perry PJ, Lund BC, Deninger MJ, Kutscher EC, Schneider J. Anabolic steroid use in weightlifters and bodybuilders: an internet survey of drug utilization. Clin J Sports Med. 2005;15(5):326–30.

    Google Scholar 

  201. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope Jr HG. Issues for DSM-V: clarifying the diagnostic criteria for ­anabolic-androgenic steroid dependence. Am J Psychiatry. 2009;166(6):642–5.

    PubMed  Google Scholar 

  202. Pope HG, Kean J, Nash A, Kanayama G, Samuel DB, Bickel WK, et al. A diagnostic interview module for anabolic-androgenic steroid dependence: preliminary evidence of reliability and validity. Exp Clin Psychopharmacol. 2010;18:203–13.

    PubMed  Google Scholar 

  203. McBride AJ, Williamson K, Petersen T. Three cases of nalbuphine hydrochloride dependence associated with anabolic steroid use. Br J Sports Med. 1996;30(1):69–70.

    PubMed  CAS  Google Scholar 

  204. Wines Jr JD, Gruber AJ, Pope Jr HG, Lukas SE. Nalbuphine hydrochloride dependence in anabolic steroid users. Am J Addict. 1999;8(2):161–4.

    PubMed  Google Scholar 

  205. Arvary D, Pope Jr HG. Anabolic-androgenic steroids as a gateway to opioid dependence. N Engl J Med. 2000;342(20):1532.

    PubMed  CAS  Google Scholar 

  206. Pope HG, Kanayama G, Ionescu-Pioggia M, Hudson JI. Anabolic steroid users’ attitudes towards physicians. Addiction. 2004;99(9):1189–94.

    PubMed  Google Scholar 

  207. Pope Jr HG, Gruber AJ, Choi P, Olivardia R, Phillips KA. Muscle dysmorphia. An underrecognized form of body dysmorphic disorder. Psychosomatics. 1997;38(6):548–57.

    PubMed  Google Scholar 

  208. Choi PY, Pope HG, Jr., Olivardia R. Muscle dysmorphia: a new syndrome in weightlifters. Br J Sports Med. 2002;36(5):375–6; discussion 377.

    Google Scholar 

  209. Kanayama G, Barry S, Hudson JI, Pope Jr HG. Body image and attitudes toward male roles in anabolic-androgenic steroid users. Am J Psychiatry. 2006;163(4):697–703.

    PubMed  Google Scholar 

  210. McKay D. Two-year follow-up of behavioral treatment and maintenance for body dysmorphic disorder. Behav Modif. 1999;23(4):620–9.

    PubMed  CAS  Google Scholar 

  211. McKay D, Todaro J, Neziroglu F, Campisi T, Moritz EK, Yaryura-Tobias JA. Body dysmorphic disorder: a preliminary evaluation of treatment and maintenance using exposure with response prevention. Behav Res Ther. 1997;35(1):67–70.

    PubMed  CAS  Google Scholar 

  212. Rosen JC, Reiter J, Orosan P. Cognitive-behavioral body image therapy for body dysmorphic disorder. J Consult Clin Psychol. 1995;63(2):263–9.

    PubMed  CAS  Google Scholar 

  213. Veale D, Gournay K, Dryden W, Boocock A, Shah F, Willson R, et al. Body dysmorphic disorder: a cognitive behavioural model and pilot randomised controlled trial. Behav Res Ther. 1996;34(9):717–29.

    PubMed  CAS  Google Scholar 

  214. Phillips KA, Rasmussen SA. Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: a placebo-controlled study. Psychosomatics. 2004;45(5):438–44.

    PubMed  Google Scholar 

  215. Phillips KA, Albertini RS, Rasmussen SA. A randomized ­placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002;59(4):381–8.

    PubMed  CAS  Google Scholar 

  216. Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999;56(11):1033–9.

    PubMed  CAS  Google Scholar 

  217. Tan RS, Scally MC. Anabolic steroid-induced hypogonadism–towards a unified hypothesis of anabolic steroid action. Med Hypotheses. 2009;72(6):723–8.

    PubMed  CAS  Google Scholar 

  218. Medras M, Tworowska U. Treatment strategies of withdrawal from long-term use of anabolic-androgenic steroids. Pol Merkur Lekarski. 2001;11(66):535–8.

    PubMed  CAS  Google Scholar 

  219. Turek PJ, Williams RH, Gilbaugh 3rd JH, Lipshultz LI. The reversibility of anabolic steroid-induced azoospermia. J Urol. 1995;153(5):1628–30.

    PubMed  CAS  Google Scholar 

  220. Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res. 2003;15(3):156–65.

    PubMed  CAS  Google Scholar 

  221. Tan RS, Carrejo MH, Chen D. An unusual case of vascular hypogonadism treated with clomiphene citrate and testosterone replacement. Andrologia. 2009;41(1):63–5.

    PubMed  CAS  Google Scholar 

  222. Tan RS, Vasudevan D. Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse. Fertil Steril. 2003;79(1):203–5.

    PubMed  Google Scholar 

  223. Carroll KM, Onken LS. Behavioral therapies for drug abuse. Am J Psychiatry. 2005;162(8):1452–60.

    PubMed  Google Scholar 

  224. Stitzer ML, Vandrey R. Contingency management: utility in the treatment of drug abuse disorders. Clin Pharmacol Ther. 2008;83(4):644–7.

    PubMed  CAS  Google Scholar 

  225. Woody GE. Research findings on psychotherapy of addictive ­disorders. Am J Addict. 2003;12 Suppl 2:S19–26.

    PubMed  Google Scholar 

Download references

Acknowledgment

This study was supported in part by United States National Institutes on Drug Abuse Grant DA016744 and DA029141.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Harrison G. Pope Jr. M.D. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Pope, H.G., Kanayama, G. (2012). Anabolic–Androgenic Steroids. In: Verster, J., Brady, K., Galanter, M., Conrod, P. (eds) Drug Abuse and Addiction in Medical Illness. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3375-0_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3375-0_19

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-3374-3

  • Online ISBN: 978-1-4614-3375-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics